PHATHOM PHARMACEUTICALS, INC. Proceeds from Long-Term Debt Issued
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Proceeds from Long-Term Debt Issued of $173.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2026-06-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $173.25M.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2025-09-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2024 was $59.40M, a 51.08% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2023 was $39.32M.
- PHATHOM PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $173.25M 10-Q · filed 2026-07-30 | $173.25M derived: sum of 3 quarters · filed 2026-07-30 | $173.25M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $173.25M 10-Q · filed 2026-04-30 | $173.25M derived: sum of 2 quarters · filed 2026-04-30 | $173.25M derived: sum of 3 quarters · filed 2026-04-30 | $173.25M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-07-30 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2026-07-30 | $0.00 10-Q · filed 2025-10-30 | $24.75M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 | $24.75M derived: sum of 3 quarters · filed 2026-07-30 | $24.75M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $24.75M derived: sum of 2 quarters · filed 2026-04-30 | $24.75M derived: sum of 3 quarters · filed 2026-04-30 | $49.50M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $24.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.75M derived: sum of 2 quarters · filed 2026-02-26 | $49.50M derived: sum of 3 quarters · filed 2026-02-26 | $59.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $24.75M derived: sum of 2 quarters · filed 2025-10-30 | $34.65M 10-Q · filed 2025-10-30 | $73.97M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $24.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $34.65M 10-Q · filed 2025-08-07 | $73.97M derived: sum of 3 quarters · filed 2025-08-07 | $73.97M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $9.90M 10-Q · filed 2025-05-01 | $49.22M derived: sum of 2 quarters · filed 2025-05-01 | $49.22M derived: sum of 3 quarters · filed 2025-05-01 | $49.22M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $39.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $39.32M derived: sum of 2 quarters · filed 2025-03-06 | $39.32M derived: sum of 3 quarters · filed 2025-03-06 | $39.32M 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-06-14 | |||
| 2022-12-31 | $0.00 10-K/A · filed 2024-06-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $96.89M 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $96.89M 10-Q/A · filed 2022-11-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $25.00M 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $25.00M 10-Q · filed 2021-11-08 | $25.00M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $25.00M 10-Q · filed 2021-08-10 | $25.00M derived: sum of 3 quarters · filed 2021-08-10 | $25.00M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $25.00M 10-Q · filed 2021-05-11 | $25.00M derived: sum of 2 quarters · filed 2021-05-11 | $25.00M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $0.00 derived: sum of 2 quarters · filed 2021-03-30 | $24.85M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $24.85M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $24.85M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |